Abstract 41P
Background
Immunotherapy has revolutionized cancer treatment improving survival rates for many cancer types. Unfortunately, resistances are common and predictive biomarkers are needed. Microsatellite Instability-high (MSI-H) usually predicts response to ICB in all tumour types, whereas we need more studies focusing on tumour mutational burden (TMB) to predict its role as a pan-cancer biomarker. Recent investigations in murine models and cohorts of patients (pts) have shown that BRCA2 PV improved response and overall survival to ICB compared to BRCA1 PV. The aim of this study was to evaluate the response to ICB in BRCA PV and its relation with TMB, MSI-H and prior treatments.
Methods
We conducted an unicohort retrospective study, between May 2020 and November 2022, in metastatic pts carrying BRCA1 or BRCA2 somatic PV and treated with ICB in phase I/II trials at Institute Gustave Roussy (France). Genomic analysis were performed by NGS (liquid biopsy and tumor samples). Data was extracted from electronic medical record and analysed with SPSS software.
Results
A total of 44 pts were enrolled. Median age was 54.6 years [range 29–74 years], 46.7% were female. Lung cancer was the most common tumour (20.5%) in an heterogenic histologic cohort of pts. Median previous lines of treatment was 2.7 [range 0-4]. Tissue analysis revealed 21.1% MSI-H, 36.8% TMB high, 23.8% BRCA1 PV, 38.1% BRCA2 PV. Blood analysis showed 7.3% MSI-H, 52.4% TMB high, 40,5% BRCA1 PV, 52.4% BRCA2 PV. All pts received immunotherapy, 69.8% ICB. The Objective Response Rate (ORR) was 34.1%. Pts with BRCA2 PV presented a better ORR to ICB compared to those with BRCA1 PV (28% vs. 4%, p = 0,030). Mean TMB was lower in BRCA2 PV than in BRCA1 PV pts and median previous lines of treatment was higher in BRCA2 PV than in BRCA1 PV (2.5 vs. 2.0). We didn´t find a significant association between BRCA1/2 PV and MSI status. Duration of response (DoR) to ICB by more than 6 months tended to be higher in pts with BRCA2 PV than those with BRCA1 PV (32% vs. 16%, p = 0,512).
Conclusions
Pts with somatic BRCA2 PV had better ORR to ICB regardless of TMB, MSI and prior lines of treatment than those with BRCA1 PV. Further research should be carried out to confirm BRCA2 as a predictive pan-cancer biomarker to ICB in a larger cohort with BRCA WT pts as comparison.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Beshiri: Financial Interests, Personal, Invited Speaker: Gustave Roussy. All other authors have declared no conflicts of interest.
Resources from the same session
74P - Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
Presenter: Monica Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Target identification by TIME phenotypes
Presenter: Robert Seitz
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
Presenter: Patrick Kirchweger
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
Presenter: Ellis Michiels
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Implementing genomic profiling as standard-of-care for glioblastoma patients
Presenter: Vincent Fougner
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
Presenter: Juanita Lopez
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Racial disparities in phase I lung cancer clinical trials
Presenter: Rohit Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract